Prostate Cancer Clinical Trial
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
Summary
Purpose: The purpose of this clinical trial is to look at the chemotherapy combination of docetaxel and capecitabine in the treatment of newly diagnosed or locally advanced prostate cancer, and to determine if this treatment is an acceptable, effective and a safe treatment option. In addition, this clinical trial will evaluate how this treatment affects chemicals (enzymes), and other cancer related genetic changes in the tumor. Optional: This clinical trial will conduct extra imaging studies for research purposes including combined endorectal prostate magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRSI) and diffusion weighted imaging (DWI) to evaluate prostate cancer and response to study treatment.
Eligibility Criteria
Patients must have newly diagnosed prostate cancer with at least one of the following criteria:
Clinical Stage > T2
PSA > 15 ng/ml
Biopsy Gleason's sum > 8
All patients must have a minimum PSA value of > 5 ng/ml.
Patients may not have evidence of distant systemic metastasis.
Patients may not undergo concurrent hormonal, biologic, or chemotherapy.
Patients may not have prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil.
Patients with a history of severe reaction to docetaxel or other drugs formulated with polysorbate 80 will not be eligible.
Patients may not have an underlying cardiac disease.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Ann Arbor Michigan, 48109, United States
Detroit Michigan, , United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.